Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) EBIT: 2009-2024

Historic EBIT for Assembly Biosciences (ASMB) over the last 14 years, with Dec 2024 value amounting to -$45.4 million.

  • Assembly Biosciences' EBIT rose 0.67% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.4 million, marking a year-over-year increase of 6.44%. This contributed to the annual value of -$45.4 million for FY2024, which is 29.74% up from last year.
  • Per Assembly Biosciences' latest filing, its EBIT stood at -$45.4 million for FY2024, which was up 29.74% from -$64.6 million recorded in FY2023.
  • In the past 5 years, Assembly Biosciences' EBIT ranged from a high of -$45.4 million in FY2024 and a low of -$132.7 million during FY2021.
  • Over the past 3 years, Assembly Biosciences' median EBIT value was -$64.6 million (recorded in 2023), while the average stood at -$68.1 million.
  • As far as peak fluctuations go, Assembly Biosciences' EBIT skyrocketed by 36.93% in 2020, and later slumped by 104.84% in 2021.
  • Assembly Biosciences' EBIT (Yearly) stood at -$64.8 million in 2020, then crashed by 104.84% to -$132.7 million in 2021, then climbed by 29.07% to -$94.1 million in 2022, then surged by 31.31% to -$64.6 million in 2023, then grew by 29.74% to -$45.4 million in 2024.